Tag: EMAG

Estimated mean change in body weight from baseline to week 64 was −13.6 and −2.2 percent with oral semaglutide and placebo, respectively

Second study shows 7.2 mg semaglutide leads to greater reductions in mean body weight for those with obesity, T2D

Factors tied to discontinuation included younger age, male sex, socioeconomic deprivation, higher comorbidity level

Semaglutide linked to increased risk of nonarteritic anterior ischemic optic neuropathy, but evidence remains insufficient to establish definitive conclusion

Association seen in seniors with type 2 diabetes; greater associations seen for semaglutide and liraglutide

Higher protein intake may be protective against muscle loss, which is tied to less improvement in glucose homeostasis

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction

Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide

Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used